Phase 2 RCT in 201 patients with advanced mycosis fungoides or Sezary syndrome: resminostat maintenance gave median PFS 8.3 vs 4.2 months with placebo (HR 0.62). Grade 3+ adverse events were higher (38% vs 15%); nausea 68% vs 6%.
RCTn = 201
Stadler et al. Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial